F2G raises $60.8m to support late-stage antifungal clinical programme
Funding will support development of novel antifungal asset olorofim
Read More
Tag: Antifungal
Manchester biotech’s novel antifungal awarded Orphan status
Manchester, UK-based biotech F2G is celebrating news that its lead clinical candidate, the antifungal F901318, has been awarded Orphan drug designation in Europe.
Read More
- Talvey accepted for use in Scotland for relapsed and refractory multiple myeloma
- Alzecure enters collaboration and with Lilly for Alzheimer’s project
- Survodutide trial data show targeted visceral and liver fat reductions
- Johnson & Johnson reports phase 2 data showing nipocalimab reduced SLE disease activity
- European approval enables measles protection with CSL’s immunoglobulin Privigen
